Last reviewed · How we verify
NCT04843111
Observational, Passive Surveillance Program to Collect Information on Women and Their Offspring Exposed to MenQuadfi® During Pregnancy, in United States (US)
trial testing Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine in Meningococcal Infection in 50 participants. Currently enrolling.
18 May 2028
Quick facts
| Lead sponsor | Sanofi Pasteur, a Sanofi Company |
|---|---|
| Status | Recruiting now |
| Study type | OBSERVATIONAL |
| Enrollment | 50 |
| Start date | 5 March 2021 |
| Primary completion | 18 May 2028 |
| Estimated completion | 18 May 2028 |
| Sites | 1 location across United States |
Drugs / interventions tested
- Meningococcal polysaccharide (serogroups A, C, Y, and W) tetanus toxoid conjugate vaccine — full drug profile →
Conditions studied
- Meningococcal Infection — all drugs for Meningococcal Infection →
Sponsor
Sanofi Pasteur, a Sanofi Company — full company profile →
Who can join
Eligibility, any sex, with Meningococcal Infection. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
Primary Objective: To assess maternal, obstetrical, pregnancy, and neonatal and infant outcomes among women vaccinated with MenQuadfi® during pregnancy or in the 30 days preceding their Last Menstrual Period (LMP).
Publications & conference data
1 peer-reviewed publication reference this trial (live from Europe PMC):
-
A new quadrivalent meningococcal tetanus toxoid conjugate vaccine: Menquadfi® (MENACWY-TT).
Dinleyici EC, Ciftci E, Somer A, Yilmaz D, et al · · 2025 · cited 2× · PMID 40493501 · DOI 10.1080/21645515.2025.2516949
Verify or expand the search:
- PubMed search for NCT04843111
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Meningococcal Infection
Currently open trials in the same condition.
- NCT07135986 — Immunogenicity and Safety Study of an Investigational Quadrivalent Meningococcal Conjugate Vaccine Administered in Healt · Phase 3 · active not recruiting
Other Sanofi Pasteur, a Sanofi Company trials
Trials by the same sponsor.
- NCT07536048 — A Longitudinal Study of Epstein-Barr Virus (EBV) Reactivation in Adults Aged 18 to 29 Years · not yet recruiting
- NCT07222059 — Phase 3 Single Arm, Open Study on vYF in Adults · Phase 3 · completed
- NCT07013747 — Study to Evaluate Safety, Efficacy and Immunogenicity of Acne mRNA Vaccine in Participants With Mild Acne · Phase 1, PHASE2 · recruiting
- NCT06838000 — Study of the Safety and Immunogenicity of Catch-up Vaccination With a 21-valent Pneumococcal Conjugate Vaccine (PCV21) i · Phase 3 · active not recruiting
- NCT06793826 — Post-marketing Surveillance Study for the Safety of a DTaP-IPV- HB-PRP~T Vaccine in Republic of Korea · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT04843111 (US National Library of Medicine, public domain)
- Publications: Europe PMC API search by NCT ID, retrieved 10 June 2026
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by Sanofi Pasteur, a Sanofi Company
- Last refreshed: 1 December 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04843111.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing